General Practice Doctors in North Attleboro, MA Accepting Medicare

1 General Practice doctors found. Showing 1 - 1

Dr. Randall Bock, M.D. General Practice Medicare: Medicare Enrolled Practice Location: 465 S Washington St, North Attleboro, MA 02760 Phone: 508-316-0725

News Archive

Key synaptic proteins could be targets for early interventions in patients with dementias

One of the most intriguing properties of the brain is its means to undergo synaptic plasticity which represents the basis for learning and memory, abilities that severely decline in the case of a dementia.

Brain research promises better understanding of schizophrenia, autism spectrum disorders

Our brain recognizes objects within milliseconds, even if it only receives rudimentary visual information. Researchers believe that reliable and fast recognition works because the brain is constantly making predictions about objects in the field of view and is comparing these with incoming information.

SDSU receives $8.5M NIH grant to develop new heart treatments using stem cells

The National Institutes of Health has awarded a prestigious Program Project Grant totaling more than $8.5 million over five-years to San Diego State University to better understand how the heart heals and ways stem cells can help the heart repair itself.

Sodium oxybate to garner over 15% of the fibromyalgia drug market despite safety concerns

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite potential safety concerns, Jazz Pharmaceuticals/UCB's sodium oxybate (JZP-6) will account for more than 15 percent of the fibromyalgia drug market in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Sodium oxybate has demonstrated robust efficacy in Phase III clinical trials for fibromyalgia and interviewed thought leaders are impressed with its effect on several key symptom domains of fibromyalgia, which include pain, sleep and fatigue.

Top-line results from Takeda vedolizumab phase 3 trial on Crohn's disease

Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.

Read more Medical News

› Verified 1 days ago